Our brief was to produce the most deliverable PTCA balloon catheter on the market.
Cape Town, South Africa (PRWEB) March 05, 2012
DISA Vascular (Pty) Limited announced this week that the company has received European (CE) approval for the newly developed Cape Cross PTCA catheter. According to CEO, Dr Greg Starke, the Cape Cross builds on the many years of clinical success that the company has enjoyed with the Explorer and Southern Cross balloon catheters. The new catheter has however been completely redesigned to meet the ever-growing needs of interventional cardiologists to treat more challenging lesions.
Product Development Manager, Ken Park, noted that the brief given to the Research and Development team was to produce the most deliverable catheter on the market. “We have achieved this through a complete redesign of each aspect of the product,” said Park. “Our new production facility has provided us with an array of state-of-the-art equipment which has enabled us to design for the most challenging performance requirements.”
The new Cape Cross catheter includes a distal tip that has been slimmed and tapered. This, together with a reduced profile and more flexible balloon-catheter bonds provides for considerably improved navigation through tortuous arteries and lesions. Pushability of the catheter has been enhanced by a newly designed hypotube and transition zone.
As part of the development process DISA Vascular has concluded a license agreement with SurModics (NYSE: SRDX) for the use of their surface modification technology, which DISA Vascular has trademarked as Contour® coating. The coating reduces friction to facilitate access and crossing of lesions, thereby increasing the trackability of the catheter through arteries during the angioplasty procedure. The Contour® coating enhances the aforementioned design attributes ensuring high-efficiency transmission of movement to the distal part of the system. The result is that the Cape Cross catheter requires significantly less force to track through a simulated tortuous anatomy when compared to major competitors.
About DISA Vascular: DISA Vascular is an innovative provider of medical devices for the treatment of coronary artery disease. For the past twelve years the company has focused on providing interventional cardiologists with dynamic products that address their clinical needs. The company’s ChromoFlex and SolarFlex coronary stents are sold in numerous countries in Europe, Africa, Asia, the Middle East and South America. For more information see http://www.disavascular.com.
About SurModics: SurModics, Inc., a leading provider of surface modification technology, licenses its patented PhotoLink® coating technology to medical device manufacturers around the world. SurModics’ hydrophilic coatings achieve performance standards—lubricity, durability, lower dynamic friction, and reduced insertion force—that are the best in the industry. For more information see http://www.surmodics.com.